Format

Send to

Choose Destination
AJR Am J Roentgenol. 2015 Aug;205(2):259-70. doi: 10.2214/AJR.14.13575.

(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis.

Author information

1
1 Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins School of Medicine, 601 N Caroline St, JHOC 3235, Baltimore, MD 21287.
2
2 Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, MD.
3
3 Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD.
4
4 Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

Abstract

OBJECTIVE:

Monoclonal antibodies that target the programmed cell death 1 (PD-1) immune checkpoint protein and its associated ligands, PD-L1 and PD-L2, and targeted inhibitors of mutated signal transduction molecules such as BRAF inhibitors show immense promise in treating patients with melanoma. We discuss the use of (18)F-FDG PET/CT for assessing therapy effectiveness, staging advanced disease, and determining prognosis of patients with melanoma.

CONCLUSION:

FDG PET/CT is useful in staging disease, assessing therapy, and determining prognosis in patients with melanoma.

KEYWORDS:

FDG PET/CT; immune modulation therapy; melanoma

PMID:
26204273
DOI:
10.2214/AJR.14.13575
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center